Calpin GG, Davey MG, Donlon NE. Management of early oesophageal cancer: An overview. World J Gastrointest Surg 2024; 16(5): 1255-1258 [PMID: 38817272 DOI: 10.4240/wjgs.v16.i5.1255]
Corresponding Author of This Article
Noel E Donlon, FRCS (Gen Surg), PhD, Assistant Professor, Department of Upper Gastrointestinal Surgery, Beaumont Hospital, Beaumont Road in Beaumont, Dublin D09V2N0, Ireland. donlonn@tcd.ie
Research Domain of This Article
Surgery
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. May 27, 2024; 16(5): 1255-1258 Published online May 27, 2024. doi: 10.4240/wjgs.v16.i5.1255
Management of early oesophageal cancer: An overview
Gavin G Calpin, Matthew G Davey, Noel E Donlon
Gavin G Calpin, Matthew G Davey, Department of Surgery, Royal College of Surgeons in Ireland, Dublin D2, Ireland
Noel E Donlon, Department of Upper Gastrointestinal Surgery, Beaumont Hospital, Dublin D09V2N0, Ireland
Author contributions: Calpin GG contributed to the manuscript drafting and revision, Davey MG contributed to conceptualisation and supervision, Donlon NE contributed to overall conceptualisation, supervision, and final draft.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Noel E Donlon, FRCS (Gen Surg), PhD, Assistant Professor, Department of Upper Gastrointestinal Surgery, Beaumont Hospital, Beaumont Road in Beaumont, Dublin D09V2N0, Ireland. donlonn@tcd.ie
Received: February 1, 2024 Revised: February 29, 2024 Accepted: April 19, 2024 Published online: May 27, 2024 Processing time: 111 Days and 15.1 Hours
Abstract
The incidence of esophageal cancer, namely the adenocarcinoma subtype, continues to increase exponentially on an annual basis. The indolent nature of the disease renders a significant proportion inoperable at first presentation, however, with the increased utilisation of endoscopy, many early lesions are now being identified which are suitable for endotherapeutic approaches. This article details the options available for dealing with early esophageal cancer by endoscopic mean obviating the need for surgery thereby avoiding the potential morbidity and mortality of such intervention.
Core Tip: Endoscopic treatment approaches have been adopted in managing early esophageal cancer in recent years. Endoscopic mucosal resection and endoscopic submucosal dissection are now considered at multidisciplinary discussions. Both are viable options and have replaced esophagectomy as the preferred treatment modality in certain cases as they are associated with reduced morbidity and mortality rates. Endotherapy is now the key treatment for early esophageal cancer with no compromise to oncological outcomes.
